|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
|
GB9710809D0
(en)
|
1997-05-23 |
1997-07-23 |
Medical Res Council |
Nucleic acid binding proteins
|
|
GB9710807D0
(en)
|
1997-05-23 |
1997-07-23 |
Medical Res Council |
Nucleic acid binding proteins
|
|
US6140081A
(en)
|
1998-10-16 |
2000-10-31 |
The Scripps Research Institute |
Zinc finger binding domains for GNN
|
|
US6534261B1
(en)
|
1999-01-12 |
2003-03-18 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
|
US6453242B1
(en)
|
1999-01-12 |
2002-09-17 |
Sangamo Biosciences, Inc. |
Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
|
|
JP2002060786A
(ja)
|
2000-08-23 |
2002-02-26 |
Kao Corp |
硬質表面用殺菌防汚剤
|
|
US20040224385A1
(en)
|
2001-08-20 |
2004-11-11 |
Barbas Carlos F |
Zinc finger binding domains for cnn
|
|
US7745140B2
(en)
|
2002-01-03 |
2010-06-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
|
|
US7888121B2
(en)
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
US7972854B2
(en)
|
2004-02-05 |
2011-07-05 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
AU2005250408B2
(en)
|
2004-05-27 |
2010-09-23 |
The Trustees Of The University Of Pennsylvania |
Novel artificial antigen presenting cells and uses therefor
|
|
WO2007146968A2
(en)
|
2006-06-12 |
2007-12-21 |
Trubion Pharmaceuticals, Inc. |
Single-chain multivalent binding proteins with effector function
|
|
HUE041436T2
(hu)
|
2009-12-10 |
2019-05-28 |
Univ Minnesota |
Tal-effektor-közvetített DNS-módosítás
|
|
EP3399026B1
(en)
|
2010-06-14 |
2024-06-26 |
The Scripps Research Institute |
Reprogramming of cells to a new fate
|
|
EP3549611B1
(en)
|
2011-07-29 |
2021-06-30 |
The Trustees of the University of Pennsylvania |
Switch costimulatory receptors
|
|
JP6850528B2
(ja)
|
2012-02-13 |
2021-03-31 |
シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート |
二重特異性キメラ抗原受容体およびその治療的使用
|
|
KR102437522B1
(ko)
|
2012-05-25 |
2022-08-26 |
셀렉티스 |
면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법
|
|
EP4303232A3
(en)
|
2013-02-15 |
2024-04-17 |
The Regents of The University of California |
Chimeric antigen receptor and methods of use thereof
|
|
AU2014248119B2
(en)
|
2013-04-03 |
2019-06-20 |
Memorial Sloan-Kettering Cancer Center |
Effective generation of tumor-targeted T-cells derived from pluripotent stem cells
|
|
US9932607B2
(en)
|
2013-11-15 |
2018-04-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Site-specific integration of transgenes into human cells
|
|
US10934346B2
(en)
|
2014-02-14 |
2021-03-02 |
Bellicum Pharmaceuticals, Inc. |
Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12
|
|
EP3656864A1
(en)
|
2014-02-14 |
2020-05-27 |
Board of Regents, The University of Texas System |
Chimeric antigen receptors and methods of making
|
|
SG11201606934SA
(en)
|
2014-03-04 |
2016-09-29 |
Fate Therapeutics Inc |
Improved reprogramming methods and cell culture platforms
|
|
CN113699159A
(zh)
|
2014-03-28 |
2021-11-26 |
明尼苏达大学评议会 |
涉及经工程改造的cd16的多肽、细胞和方法
|
|
US10888608B2
(en)
|
2014-09-02 |
2021-01-12 |
Bellicum Pharmaceuticals, Inc. |
Costimulation of chimeric antigen receptors by MyD88 and CD40 polypeptides
|
|
SG10202111851YA
(en)
|
2015-10-16 |
2021-12-30 |
Fate Therapeutics Inc |
Platform for the Induction & Maintenance of Ground State Pluripotency
|
|
CA3003152A1
(en)
|
2015-11-04 |
2017-05-11 |
Fate Therapeutics, Inc. |
Methods and compositions for inducing hematopoietic cell differentiation
|
|
JP6928604B2
(ja)
*
|
2015-11-04 |
2021-09-01 |
フェイト セラピューティクス，インコーポレイテッド |
万能性細胞のゲノム改変
|
|
JP2019506143A
(ja)
|
2015-12-14 |
2019-03-07 |
ベリカム ファーマシューティカルズ， インコーポレイテッド |
治療用細胞の活性化及び排除のための二重コントロール
|
|
EP3405568A4
(en)
|
2016-01-20 |
2019-12-04 |
Fate Therapeutics, Inc. |
COMPOUNDS AND METHODS FOR IMMUNOCELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES
|
|
JP7554670B2
(ja)
|
2017-10-11 |
2024-09-20 |
フェイト セラピューティクス，インコーポレイテッド |
一時的かつ一過性プラスミドベクター発現システムを用いる細胞のリプログラミング
|
|
US20210015859A1
(en)
*
|
2017-12-08 |
2021-01-21 |
Fate Therapeutics, Inc. |
IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS
|
|
CA3083779A1
(en)
*
|
2017-12-22 |
2019-06-27 |
Fate Therapeutics, Inc. |
Enhanced immune effector cells and use thereof
|
|
JP7575271B2
(ja)
*
|
2018-03-29 |
2024-10-29 |
フェイト セラピューティクス，インコーポレイテッド |
操作された免疫エフェクター細胞およびその使用
|
|
KR102943217B1
(ko)
*
|
2018-12-02 |
2026-03-25 |
페이트 세러퓨틱스, 인코포레이티드 |
향상된 iPSC 유래 효과기 세포를 사용한 면역요법
|
|
AU2020271523A1
(en)
|
2019-04-11 |
2021-10-14 |
Fate Therapeutics, Inc. |
CD3 reconstitution in engineered iPSC and immune effector cells
|